Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | CBS | P35520 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CD69 | Q07108 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431399 | 0.83 | — | — | |
| SCHEMBL7682659 | 0.83 | TSHR (0.41) | TSHRSMN1; SMN2CTHCBSTHPO | |
| SCHEMBL14793371 | 0.83 | HMGCR (0.39) | TSHRSMN1; SMN2CTHCBSTHPO | |
| SCHEMBL18679947 | 0.81 | KDM4E (0.38) | TSHRSMN1; SMN2CTHCBSTHPO | |
| SCHEMBL27975146 | 0.80 | TSHR (0.39) | TSHRSMN1; SMN2CTHCBSTHPO | |
| SCHEMBL20257647 | 0.79 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL12768993 | 0.78 | SMN1; SMN2 (0.32) | TSHRSMN1; SMN2CTHCBSTHPO | |
| SCHEMBL19203186 | 0.78 | ALDH1A1 (0.33) | TSHRHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL14150083 | 0.76 | TSHR (0.36) | TSHRSMN1; SMN2CTHCBSTHPO | |
| SCHEMBL2560726 | 0.76 | TSHR (0.38) | TSHRSMN1; SMN2CTHCBSTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230304188-A1 | LUMINESCENT CRYSTALS AND MANUFACTURING THEREOF | AVANTAMA AG (CH) | 2023-09-28 | — | — | US | disclosed |
| US-11702762-B2 | Luminescent crystals and manufacturing thereof | AVANTAMA AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-11414597-B2 | Luminescent crystals and manufacturing thereof | AVANTAMA AG (CH) | 2022-08-16 | — | — | US | disclosed |
| US-20220195295-A1 | LUMINESCENT CRYSTALS AND MANUFACTURING THEREOF | AVANTAMA AG (CH) | 2022-06-23 | — | — | US | disclosed |
| US-10920137-B2 | Luminescent crystals and manufacturing thereof | AVANTAMA AG (CH) | 2021-02-16 | — | — | US | disclosed |
| US-10246573-B2 | Anti-static compositions | HONEYWELL INTERNATIONAL INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180208840-A1 | LUMINESCENT CRYSTALS AND MANUFACTURING THEREOF | AVANTAMA AG (CH) | 2018-07-26 | — | — | US | disclosed |
| US-20170218179-A1 | ANTI-STATIC COMPOSITIONS | HONEYWELL SAFETY PRODUCTS USA, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230304188-A1 | LUMINESCENT CRYSTALS AND MANUFACTURING THEREOF | C1QBP, LAS1L, C1S | TSHR 4046/4885SMN1; SMN2 3890/4885CTH 4229/4885 |
| US-11702762-B2 | Luminescent crystals and manufacturing thereof | C1QBP, LAS1L, C1S | TSHR 4046/4885SMN1; SMN2 3890/4885CTH 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.